FACULTY

Dr Christian Rolfo
Dr Christian Rolfo

ISLB President Mount Sinai Medical System & Icahn School of Medicine, Mount Sinai, New York, NY, USA.

press to zoom
Dr Maria José Serrano
Dr Maria José Serrano

The trajectory Dr. María José Serrano is based on oncological research and mainly focused on the area of liquid biopsy, with more than 23 years of an experience in this type of analyses. During her career she has made different stays in Spain (Bilbao, Pamplona, Barcelona) and abroad (Tromso Norway). Currently, she is Principal investigator of the Liquid Biopsy and Cancer Interception group (LiqBiopCI) at GENyO center and in the Oncology department in the Uni Hospital Virgen de las Nieves.

press to zoom
Dr Umberto Malapelle
Dr Umberto Malapelle

Umberto Malapelle is the Chair of Predictive Molecular Pathology Laboratory, of the University of Naples Federico II.He was appointed in December 2015 Assistant Professor in Anatomic Pathology in School of Medicine, University of Naples Federico II. Currently his main research interest is in the field of genomic biomarkers validation and testing for predictive information in the field of lung cancer, metastatic colorectal cancer, melanoma and gastrointestinal stromal tumor.

press to zoom
Dr David Gandara
Dr David Gandara

University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA David R. Gandara, MD is a Professor of Medicine at the University of California at Davis (UCD) School of Medicine, is the Senior Advisor to the Director, and Director of the Thoracic Oncology Program at UC Davis Comprehensive Cancer Center (UCDCCC). He is a diplomat of the American Board of Internal Medicine specializing in Medical Oncology.

press to zoom
Dr Eloisa Jantus
Dr Eloisa Jantus

ELOISA JANTUS LEWINTRE is Associate Professor at the Department of Biotechnology, Polytechnic University of Valencia, Head of the Molecular Oncology Laboratory at General University Hospital of Valencia Research Foundation, Co-PI in the Respiratory Tract Tumors Program of the Spanish Oncology Network of Biomedical Research (CIBERONC) and member of the Board of Directors of ISLB. She authored more than 80 articles in the oncology area (H-index: 20).

press to zoom
Dr Charles Swanton
Dr Charles Swanton

Charles completed his MDPhD training in 1999 at the Imperial Cancer Research Fund Laboratories and Cancer Research UK clinician scientist/medical oncology training in 2008. Charles is a senior group leader of the Cancer Evolution and Genome Instability Laboratory at the Francis Crick Institute  and combines his research with clinical duties at UCLH, as a thoracic oncologist, focussed on how tumours evolve over space and time. Charles research branched evolutionary histories of solid tumours.

press to zoom
Dr Catherine Alix-Panabieres
Dr Catherine Alix-Panabieres

Dr Catherine Alix-Panabières received her PhD-degree in Strasbourg (1998). She is associate professor - director of the LCCRH at the UMC Montpellier. These last 22 years, she put huge efforts on the analysis of CTCs in cancer patients. She coined for the first time ‘Liquid Biopsy’ in 2010 with Klaus Pantel. She authored >110 scientific publications and is the inventor of 3 patents in the liquid biopsy field. She is involved in many national and international liquid biopsy-based clinical trials.

press to zoom
Dr Juan Manuel Falcón
Dr Juan Manuel Falcón

IKERBASQUE Prof at CIC bioGUNE (Spain). Head of EXOSOMES lab and METABOLOMICS platform. Biochemistry and cellular biologist with wide experience in performing omics-based analyses. Since 2006, study EXOSOMES as disease biomarker and a tool for therapeutic applications. He has characterized EVs secreted by in vivo and in vitro experimental models of several diseases, and from bodily fluids, >50 publications related with extracellular vesicles. GEIVEX co-founder and part of the board of ISEV.

press to zoom
Dr Sabine Kasimir-Bauer
Dr Sabine Kasimir-Bauer

Associate Professor, University of Duisburg Essen, Germany

press to zoom
Dr Nicola Aceto
Dr Nicola Aceto

Dr Aceto is Prof of Molecular Oncology at the ETH Zurich. Previously, he was an Assistant Prof of Oncology at the Univ of Basel, Switzerland, and prior to that, postdoctoral fellow at Harvard Medical School and MGH Cancer Center Boston, USA. Recent discoveries of the Aceto lab include important insights into the metastatic process, namely investigations of the biology and vulnerabilities of CTC clusters, some of which already translated in clinical trials for patients with metastatic breast canc

press to zoom
Dr Héctor Peinado
Dr Héctor Peinado

I did my PhD in the laboratory of Dr. Amparo Cano in Madrid in 2003. I joined Dr. Lyden’s laboratory at Weill Cornell Medicine, New York in 2008, my work there defined that tumor- secreted exosomes in pre-metastatic niche formation. I joined CNIO in 2015 as the group leader of the laboratory of Microenvironment and Metastasis. My current research goals are focused on understanding the role of tumor-secreted extracellular vesicles during metastasis and the use of extracellular vesicles in LB

press to zoom
Dr Kenneth O'Byrne
Dr Kenneth O'Byrne

Consultant Medical Oncologist Princess Alexandra Hospital, Translational Research Institute and Queensland University of Technology, Brisbane, Australia

press to zoom
Dr Lynette M. Sholl
Dr Lynette M. Sholl

Dr. Sholl is a pathologist at Brigham and Women’s Hospital (BWH) in Boston and Associate Professor of Pathology at Harvard Medical School. She completed her medical schooling at Stanford University School of Medicine, followed by internal medicine internship at the Hospital of University of Pennsylvania, anatomic pathology residency at BWH, and the molecular genetics pathology fellowship at Harvard.

press to zoom
Dr Philip Mack
Dr Philip Mack

University of California Davis Comprehensive Cancer Center, Sacramento, CA - Mount Sinai Tisch Cancer Institute, New York, NY

press to zoom
Dr Miguel Angel Molina-Vila
Dr Miguel Angel Molina-Vila

Miguel Ángel Molina-Vila holds a PhD in Biochemistry and Molecular Biology. During a 25 year experience in translational research, in hospitals such as MD Anderson Cancer Center or Vall d’Hebron Hospital, he has co-authored of more than 90 peer reviewed publications in cancer and medical journals. A member of the Scientific Committee of the Spanish Lung Cancer Group (SLCG), he is currently the Technical Director of the Laboratory of Oncology at the Quiron Dexeus University Hospital, in Barcelona

press to zoom
Dr Federica Di Nicolantonio
Dr Federica Di Nicolantonio

Prof Di Nicolantonio holds a joint appointment as Director of the Laboratory of Cancer Epigenetics at the Candiolo Cancer Institute in Italy and as Associate Professor in biochemistry at the University of Torino. Her research focuses on the molecular mechanisms underlying cancer cells' response to antineoplastic drugs using a combination of preclinical models, and patient tissue and liquid biopsies.

press to zoom
Dr Natasha Leighl
Dr Natasha Leighl

Medical Oncology, Princess Margaret, Toronto, ON, Canada

press to zoom
Dr Charu Aggarwal
Dr Charu Aggarwal

Dept of Medicine, Division of Hem/Onc, University of Pennsylvania, PA, USA

press to zoom
Dr Maria E. Arcila
Dr Maria E. Arcila

Memorial Sloan-Kettering Cancer Center, New York, NY, USA

press to zoom
Dr Sarah-Jane Dawson
Dr Sarah-Jane Dawson

University of Melbourne, Australia

press to zoom
Dr Heinz Josef Lenz
Dr Heinz Josef Lenz

University of South California USC, USA

press to zoom
Dr Chiara Cremolini
Dr Chiara Cremolini

Chiara Cremolini is an Associate Professor in Medical Oncology at the University of Pisa in Italy. She actively contributes to clinical trials by Gruppo Oncologico del Nord Ovest (GONO), an Italian Foundation involved in the design and conduction of clinical and translational studies in the field of several solid malignancies, serving as Scientific Secretary from 2015 to 2021 and as President since April 2021, and participates to the activity of the ESMO Faculty Member for the GI tumors.

press to zoom
Dr Sergio Marchini
Dr Sergio Marchini

IRCCS, Humanitas Research Hospital, Milan, Italy

press to zoom
Dr Johann De Bono
Dr Johann De Bono

The Institute of Cancer Research and The Royal Marsden Hospital, Sutton, UK

press to zoom
Dr Lillian Siu
Dr Lillian Siu

Princess Margaret, Ontario, Canada Dr. Lillian Siu is a senior medical oncologist at Princess Margaret Cancer Centre, and a Professor of Medicine at the University of Toronto. She is the Director of the Phase I Program, Clinical Lead for the Tumor Immunotherapy Program, and holds the BMO Chair in Precision Genomics. She is the PI of the institutional liquid biopsy program LIBERATE at the Princess Margaret. Dr. Siu has previously served on both the Board of Directors for ASCO and AACR.

press to zoom
Dr Pier Vitale Nuzzo
Dr Pier Vitale Nuzzo

Dana Farber Cancer Institute, Boston, MA, USA

press to zoom
Dr Alberto Bardelli
Dr Alberto Bardelli

Full Professor (University of Torino) and Director of the Laboratory of Molecular Oncology(Candiolo Cancer Institute-IRCCS, Candiolo, Italy). As a postdoc in the group of Bert Vogelstein (Johns Hopkins University), he performed the first comprehensive mutational profile of protein and lipid kinases in CRC. He focuses on precision oncology and pioneered the use of liquid biopsies to track cancer evolution during therapy.

press to zoom
Dr Toni choueiri
Dr Toni choueiri

Dana Farber Cancer Institute, Boston, MA, USA

press to zoom
Dr Luis Raez
Dr Luis Raez

Memorial Healthcare System, Pembroke Pines, USA

press to zoom
Dr Nicole Kruderer
Dr Nicole Kruderer

Medical Director Advanced Cancer Research Group Kirkland, Washington

press to zoom
Dr Andrés Cardona
Dr Andrés Cardona

Clínica del Country, Bogotá, Colombia

press to zoom
Dr Max Diehn
Dr Max Diehn

Stanford University, Stanford, CA, USA Dr. Max Diehn is the CRK Faculty Scholar and Associate Professor, Division Chief of Radiation and Cancer Biology, and Vice Chair of Research in the Department of Radiation Oncology at Stanford University. He is a physician scientist and practicing radiation oncologist whose main research focus is on the development and application of liquid biopsy technologies for cancer screening, treatment response assessment, and detection of minimal residual disease.

press to zoom
Dr Wishart David
Dr Wishart David

Dr. David Wishart is a Distinguished University Professor in the Departments of Biological Sciences and Computing Science at the University of Alberta. He also holds adjunct appointments with the Faculty of Pharmaceutical Sciences and with the Department of Pathology and Laboratory Medicine. He has been with the University of Alberta since 1995. Dr. Wishart has been studying protein folding and misfolding for more than 30 years using a combination of computational and experimental approaches

press to zoom
Dr Aadel Chaudhuri
Dr Aadel Chaudhuri

Washington University School of Medicine, St. Louis, USA

press to zoom
Dr Chris Abbosh
Dr Chris Abbosh

Chris Abbosh is a principal clinical fellow in medical oncology at University College London, UK. He works on the Cancer Research UK funded lung TRACERx study, led by Professor Charles Swanton and funded by Cancer Research UK. Chris’s role within this study has been developing non-invasive biomarker strategies for lung cancer. His focus has been evaluating circulating tumor DNA (ctDNA) in terms of biology underpinning ctDNA release, use of ctDNA as a minimal residual disease biomarker

press to zoom
Dr Amy Moore
Dr Amy Moore

Dr. Amy Moore is the VP, Global Engagement and Patient Partnerships for LUNGevity Foundation. In that role, she seeks to build collaborations with stakeholders around the world to broaden clinical trials availability and access, to increase utilization of comprehensive biomarker testing and precision medicine and to understand regulatory and policy issues that impact delivery of optimal lung cancer care. As a trained virologist, she also serves as LUNGevity’s lead on all things related to COVID

press to zoom
RN, ONC, Allison Gittens
RN, ONC, Allison Gittens

Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD, USA

press to zoom
Dr Valeria Denninghoff
Dr Valeria Denninghoff

University of Buenos Aires (UBA) - National Council for Scientific and Technical Research (CONICET), Argentina

press to zoom
Dr Ullas Batra
Dr Ullas Batra

Rajiv Gandhi Cancer Institute, Delhi, India

press to zoom
Dr Ola Khorshid
Dr Ola Khorshid

Dr Ola Khorshid is currently a Prof. of Medical Oncology, Malignant Hematology & BMT, Medical Oncology Department NCI, Cairo University She is the Chairman & Founder of Millennium HealthCare institution Chairman of Onco thoracic International Clinical Association OnTiC Cofounder of Orchid Oncology Center Secretary General of the Mediterranean Multidisciplinary Oncology Forum (MMOF) She received her master (1998) and PhD (2004) degrees in medical oncology and hematological malignancies from th

press to zoom
Dr Cardinale Smith
Dr Cardinale Smith

Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai and Chief Quality Officer for Cancer Services at the Mount Sinai Tisch Cancer Center. Her clinical focus is on lung cancer and palliative care. She is an RO1 funded clinical investigator whose work focuses on clinician-patient communication, evaluating treatment disparities and interventions focused on eliminating barriers to high quality cancer care delivery among racial and ethnic minorities.

press to zoom
Dana Connors
Dana Connors

ILSA, Foundation for the National Institutes of Health, USA

press to zoom